LAGENDORFF'S HEART PREPARATION

EVALUATION OF MUSCARINIC RECEPTOR ACTIVITY OF DOXORUBIC

Abstract

Doxourbicin (Dox) is an effective anticancer chemotherapeutic agent, for the treatment of several different human cancers, causes an insidious and delayed cardiotoxicity. Its use is limited, as cardiac toxicity occurs above a cumulative dose 450 mgrrr2 and incidence of this toxicity increases markedly at dose2 greater than 550 mgrrr2. Pre-clinical investigations are attempting to elucidate the doxorubicin induced cardiotoxcity drugs are used to scavenge the toxicity or to determine the possible mechanisms of this cardiac toxicity. Role of autonomic nervous system in this regard has extensively been investigated. We have tried to find the physiological interactions of DOX with muscarinic receptors in presence of Atropine (Antagonist) and evaluated the effects for up and down regulation of muscarinic receptors. The results showed synergistic activity of DOX with atropine and hence DOX is said to be a muscarinic, antagonist.